Compare Natera Inc. Common Stock (NTRA) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Western Alliance Bancorporation — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Western Alliance Bancorporation trades at $72.03 (market cap $8.04B). The key difference: Natera Inc. Common Stock is far larger — about 7.1× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays a 2.28% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Western Alliance Bancorporation for 3 Days on average.
| NTRA | WAL | |
|---|---|---|
Market Cap | $57.03B | $8.04B |
Volume | 1,131,157 | 1,433,355 |
Sector | Health | Financials |
52-Week High | $425.64 | $96.08 |
52-Week Low | $179.42 | $66.70 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $56.18B | $9.57B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Western Alliance Bancorporation (WAL) trades at $73.73, down 1.29% on the day, reflecting a bearish technical signal despite strong fundamentals. The stock shows solid profitability with a 25.43% net income margin and attractive valuation ratios, including a P/E of 8.32. Recent earnings have mostly beaten estimates, and the company launched WA VenueX, a new financial platform. Analyst consensus is strongly bullish with a $85.09 price target, though technical indicators point to near-term weakness.
The outlook for WAL is positive based on fundamentals and analyst support, but technical headwinds and interest rate sensitivity pose risks. Upside potential exists if the stock rebounds from support levels and executes on growth initiatives, while downside could stem from macroeconomic pressures or missed earnings. The high institutional ownership and recent dividend announcement signal confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
